BMS/AbbVie where awarded Breakthrough status for Elotuzumab last night in combination through a Phase II completed last year although currently in Phase III. What's worth noting though is the NK cells in the above and observations made in analysis of patients own immune systems post SM6 trial.
Just saying......
good for pab/sm6, page-7
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.002(33.3%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $95.25K | 26.45M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 29109964 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 19424458 | 8 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |